PRCT on Nasdaq
PROCEPT BioRobotics Corp
We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology.1
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with SkinHealth Systems Inc., ANGIODYNAMICS INC or TACTILE SYSTEMS TECHNOLOGY INC, or pick any stock.
- TickerPRCT on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersSan Jose, California1
- Incorporated inDE2
- Business address150 Baytech Drive, San Jose, Ca 951342
- Filer categoryLarge accelerated filer2
See how the biggest companies compare on our leaderboards
We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. Each of our robotic systems employs a single-use disposable handpiece to deliver our proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. We designed our robotic systems to enable consistent and reproducible BPH surgery outcomes. We believe t…3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
63.7%Gross margin4
-33.7%Operating margin4
-31.0%Net margin4
37.2%Revenue growth, 20254
-26.1%Return on equity4
0.14×Debt to equity4
-$58.3MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 88% of the revenue PROCEPT BioRobotics Corp broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $124.3M | $200.5M | $270.4M |
| Outside the United States | $11.9M | $24.0M | $37.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue27¢$111.8M
- Research and development17¢$71.3M
- Selling, general and admin56¢$228.8M
- Income tax0¢$190.0K
Out of $308.1M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $308.1M | $224.5M | $136.2M |
| Cost of sales | $111.8M | $87.4M | $65.1M |
| Gross profit | $196.2M | $137.1M | $71.0M |
| Research and development | $71.3M | $62.3M | $48.4M |
| Selling, general and administrative | $228.8M | $171.4M | $131.8M |
| Total operating expenses | $300.1M | $233.7M | $180.2M |
| Loss from operations | -$103.9M | -$96.6M | -$109.2M |
| Interest expense | -$3.6M | -$4.2M | -$4.0M |
| Interest and other income (expenses), net | $12.1M | $9.8M | $7.3M |
| Loss before income taxes | -$95.4M | -$91.0M | -$105.8M |
| Provision for income taxes | $190.0K | $368.0K | $80.0K |
| Net loss | -$95.6M | -$91.4M | -$105.9M |
| Net loss per share, basic (in dollars per share) | -$1.72 | -$1.75 | -$2.24 |
| Net loss per share, diluted (in dollars per share) | -$1.72 | -$1.75 | -$2.24 |
| Basic (in shares) | 55.5M shares | 52.1M shares | 47.3M shares |
| Diluted (in shares) | 55.5M shares | 52.1M shares | 47.3M shares |
| Foreign currency translation adjustment | -$77.0K | $0 | $0 |
| Unrealized gain on cash equivalents | $0 | $30.0K | $90.0K |
| Comprehensive loss | -$95.6M | -$91.4M | -$105.8M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $286.5M | $333.7M | $257.2M | |
| Accounts receivable, net, | $83.5M | $83.5M | ||
| Inventory | $70.7M | $56.2M | ||
| Prepaid expenses and other current assets | $9.6M | $8.5M | ||
| Total current assets | $450.4M | $481.8M | ||
| Restricted cash, non-current | $3.0M | $3.0M | ||
| Property and equipment, net | $30.4M | $26.7M | ||
| Operating lease right-of-use assets, net | $17.5M | $18.9M | ||
| Intangible assets, net | $709.0K | $932.0K | ||
| Other assets | $6.0M | $2.6M | ||
| Total assets | $508.1M | $534.0M | ||
| Accounts payable | $17.3M | $10.0M | ||
| Accrued compensation | $23.2M | $21.5M | ||
| Deferred revenue | $13.0M | $9.6M | ||
| Operating leases, current | $2.2M | $1.9M | ||
| Loan facility derivative liability | $0 | $2.0M | ||
| Other current liabilities | $10.1M | $8.1M | ||
| Total current liabilities | $65.8M | $53.1M | ||
| Long-term debt | $51.6M | $51.5M | ||
| Operating leases, non-current | $24.7M | $26.9M | ||
| Other non-current liabilities | $147.0K | $324.0K | ||
| Total liabilities | $142.2M | $131.8M | ||
| Preferred stock, $0.00001 par value; authorized shares: 10,000 at December 31, 2025 and 2024, respectively Issued and outstanding shares: none at December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.00001 par value; authorized shares: 300,000 at December 31, 2025 and 2024, respectively Issued and outstanding shares: 54,718 and 50,771 at December 31, 2025 and 2024 | $0 | $0 | ||
| Additional paid-in capital | $1.0B | $948.1M | ||
| Accumulated other comprehensive gain | $37.0K | $114.0K | ||
| Accumulated deficit | -$641.6M | -$546.0M | ||
| Total stockholders equity | $365.9M | $402.2M | $280.8M | $197.1M |
| Total liabilities and stockholders equity | $508.1M | $534.0M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred Stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred Stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued (in shares) | 56.3M shares | 54.7M shares | ||
| Common stock, shares, outstanding (in shares) | 56.3M shares | 54.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $286.5M | $333.7M | $257.2M | |
| Accounts receivable, net, | $83.5M | $83.5M | ||
| Inventory | $70.7M | $56.2M | ||
| Prepaid expenses and other current assets | $9.6M | $8.5M | ||
| Total current assets | $450.4M | $481.8M | ||
| Restricted cash, non-current | $3.0M | $3.0M | ||
| Property and equipment, net | $30.4M | $26.7M | ||
| Operating lease right-of-use assets, net | $17.5M | $18.9M | ||
| Intangible assets, net | $709.0K | $932.0K | ||
| Other assets | $6.0M | $2.6M | ||
| Total assets | $508.1M | $534.0M | ||
| Accounts payable | $17.3M | $10.0M | ||
| Accrued compensation | $23.2M | $21.5M | ||
| Deferred revenue | $13.0M | $9.6M | ||
| Operating leases, current | $2.2M | $1.9M | ||
| Loan facility derivative liability | $0 | $2.0M | ||
| Other current liabilities | $10.1M | $8.1M | ||
| Total current liabilities | $65.8M | $53.1M | ||
| Long-term debt | $51.6M | $51.5M | ||
| Operating leases, non-current | $24.7M | $26.9M | ||
| Other non-current liabilities | $147.0K | $324.0K | ||
| Total liabilities | $142.2M | $131.8M | ||
| Preferred stock, $0.00001 par value; authorized shares: 10,000 at December 31, 2025 and 2024, respectively Issued and outstanding shares: none at December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.00001 par value; authorized shares: 300,000 at December 31, 2025 and 2024, respectively Issued and outstanding shares: 54,718 and 50,771 at December 31, 2025 and 2024 | $0 | $0 | ||
| Additional paid-in capital | $1.0B | $948.1M | ||
| Accumulated other comprehensive gain | $37.0K | $114.0K | ||
| Accumulated deficit | -$641.6M | -$546.0M | ||
| Total stockholders equity | $365.9M | $402.2M | $280.8M | $197.1M |
| Total liabilities and stockholders equity | $508.1M | $534.0M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred Stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred Stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued (in shares) | 56.3M shares | 54.7M shares | ||
| Common stock, shares, outstanding (in shares) | 56.3M shares | 54.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$95.6M | -$91.4M | -$105.9M |
| Depreciation and amortization | $6.4M | $5.2M | $3.8M |
| Stock-based compensation expense | $47.6M | $31.8M | $19.1M |
| Change in fair value in derivative liability | $0 | $114.0K | $107.0K |
| Non-cash lease adjustment | -$508.0K | -$383.0K | $13.0K |
| Provision for credit losses | $219.0K | $840.0K | $0 |
| Inventory write-down | $565.0K | $1.9M | $995.0K |
| (Gain) loss on foreign currency transactions | $157.0K | $0 | $0 |
| Accounts receivable, net | -$898.0K | -$36.0M | -$33.1M |
| Inventory | -$14.5M | -$17.2M | -$9.8M |
| Prepaid expenses and other current assets | -$1.1M | -$3.2M | $1.1M |
| Other assets | -$2.9M | -$1.6M | -$868.0K |
| Accounts payable | $6.6M | -$2.2M | $5.8M |
| Accrued compensation | $1.6M | $4.7M | $3.4M |
| Accrued interest expense | $142.0K | $134.0K | $125.0K |
| Loan facility liability | -$2.0M | $0 | $0 |
| Deferred revenue | $3.3M | $3.7M | $3.3M |
| Reimbursements for leasehold improvements from operating leases | $0 | $2.6M | $5.0M |
| Other liabilities | $1.9M | $1.8M | -$1.1M |
| Net cash used in operating activities | -$49.0M | -$99.2M | -$108.0M |
| Purchases of property and equipment | -$9.4M | -$4.4M | -$25.2M |
| Net cash used in investing activities | -$9.4M | -$4.4M | -$25.2M |
| Proceeds from issuance of common stock under employee stock purchase plan | $6.4M | $4.5M | $3.6M |
| Proceeds from issuance of common stock from the exercise of stock options, net | $4.8M | $11.1M | $2.5M |
| Proceeds from issuance of common stock, net of issuance costs | $0 | $164.5M | $161.7M |
| Net cash provided by financing activities | $11.2M | $180.1M | $167.8M |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -$74.0K | $0 | $0 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -$47.2M | $76.5M | $34.6M |
| Interest paid | $3.5M | $4.0M | $4.1M |
| Property and equipment included in accounts payable and accrued expenses | $969.0K | $348.0K | $1.9M |
No quarter-by-quarter statement was filed.
Leadership
Who has led PROCEPT BioRobotics Corp, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2025
- Chief executive officerLarry L. Wood Sep 4, 2025 to now11
- Chief executive officerReza Zadno Sep 14, 2021 to Sep 4, 202512
- PresidentLarry L. Wood Sep 4, 2025 to now11
- PresidentReza Zadno Sep 14, 2021 to Sep 4, 202512
- Chief financial officerKevin Waters Sep 14, 2021 to now13
Board members and other officers (16)
- Chief Strat/Marketing OfficerPooja Sharma Apr 24, 2026 to now14
- EVP, Chief Technology OfficerBarry L. Templin Apr 30, 2026 to now15
- SVP, GEN COUNSEL, CORP. SEC.Alaleh Nouri Sep 14, 2021 to Sep 14, 202116
- SVP, Commercial OperationsHisham Shiblaq Sep 14, 2021 to now17
- Board memberLarry L. Wood Apr 19, 2024 to now18
- Board memberThomas M. Prescott Jul 19, 2024 to now19
- Board memberMary Garrett Jan 3, 2022 to now20
- Board memberAmy M. Dodrill Sep 14, 2021 to now21
- Board memberAntal Rohit Desai Sep 14, 2021 to now22
- Board memberFrederic H. Moll Sep 14, 2021 to now23
- Board memberMorgan Colby Wood Sep 14, 2021 to Nov 14, 202324
- Board memberReza Zadno Sep 14, 2021 to now12
- Board memberTaylor C. Harris Sep 14, 2021 to now25
- Board memberThomas M. Krummel Sep 14, 2021 to Jun 6, 202426
- Board memberElisabeth Sandoval Oct 25, 2021 to now27
- General counselAlaleh Nouri Apr 4, 2022 to now28
Timeline
Filings
339 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 47 major events, 173 insider forms, 30 large holders, 67 other. The latest 20:
- Oct 5, 20264 EDGAR
- Oct 5, 20263 EDGAR
- Oct 2, 20268-K EDGAR
- Sep 24, 20268-K EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 9, 2026144 EDGAR
- Sep 9, 2026144 EDGAR
- Sep 9, 2026144 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 10, 20264 EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Jul 29, 2026SCHEDULE 13G/A EDGAR
- Jun 10, 20264 EDGAR
- Jun 10, 20264 EDGAR
The 339 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
97 open-market trades by officers, directors and large owners since October 2021: 6 buys and 91 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Waters KevinEVP, CFO | Sale | 373 | $20.95 | $7.8K | Form 4 |
| Sep 9, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sale | 297 | $20.95 | $6.2K | Form 4 |
| Sep 9, 2026 | Templin Barry LEVP, Chief Technology Officer | Sale | 373 | $20.95 | $7.8K | Form 4 |
| Aug 7, 2026 | Wood Larry LPresident, CEO | Buy | 23,900 | $20.85 | $498.3K | Form 4 |
| Jun 8, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sale | 285 | $28.48 | $8.1K | Form 4 |
| Jun 8, 2026 | Waters KevinEVP, CFO | Sale | 357 | $28.48 | $10.2K | Form 4 |
| Jun 8, 2026 | Templin Barry LEVP, Chief Technology Officer | Sale | 358 | $28.48 | $10.2K | Form 4 |
| Mar 19, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sale | 5,363 | $25.96 | $139.2K | Form 4 |
| Mar 17, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sale | 304 | $28.15 | $8.6K | Form 4 |
| Mar 17, 2026 | Waters KevinEVP, CFO | Sale | 706 | $28.15 | $19.9K | Form 4 |
| Mar 10, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sale | 3,243 | $25.65 | $83.2K | Form 4 |
| Mar 9, 2026 | Desai Antal RohitDirector | Buy | 98,699 | $24.55 | $2.4M | Form 4 |
| Mar 6, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sale | 6,892 | $23.70 | $163.3K | Form 4 |
| Mar 6, 2026 | Waters KevinEVP, CFO | Sale | 6,721 | $23.70 | $159.3K | Form 4 |
| Mar 6, 2026 | Desai Antal RohitDirector | Buy | 160,317 | $23.59 | $3.8M | Form 4 |
| Mar 5, 2026 | Desai Antal RohitDirector | Buy | 167,246 | $25.58 | $4.3M | Form 4 |
| Aug 13, 2025 | MOLL FREDERIC HDirector | Buy | 20,000 | $39.26 | $785.2K | Form 4 |
| Jun 12, 2025 | Desai Antal RohitDirector | Sale | 25,000 | $61.49 | $1.5M | Form 4 |
| Jun 11, 2025 | Desai Antal RohitDirector | Sale | 25,000 | $63.38 | $1.6M | Form 4 |
| Jun 10, 2025 | Desai Antal RohitDirector | Sale | 25,000 | $63.91 | $1.6M | Form 4 |
All 97 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BlackRockSCHEDULE 13G/A, 1 filing Jul 29, 202629
- AllianceBernsteinSCHEDULE 13G/A, 2 filings Nov 14, 2025 to May 18, 202630
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202631
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 9, 2023 to Mar 27, 202632
- FMR LLCSCHEDULE 13G/A, 6 filings Feb 9, 2022 to Mar 6, 202633
- T. Rowe Price Investment Management, Inc.SCHEDULE 13G, 4 filings Feb 14, 2023 to Feb 17, 202634
- BNP Paribas Asset Management Holding S.A.SCHEDULE 13G, 1 filing Feb 11, 202635
- CPMG IncSC 13D/A, 6 filings Sep 8, 2022 to May 22, 202436
- VIKING GLOBAL INVESTORS LPSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 202337
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 4,869,828 | $110.0M | 0.0% | +507,826 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2,823,849 | $63.8M | 0.1% | −265,529 |
| Vanguard Portfolio Management LLC | 2,526,802 | $57.1M | 0.0% | +105,440 |
| Vanguard Capital Management LLC | 2,460,802 | $55.6M | 0.0% | +61,735 |
| Chicago Capital, LLC | 2,073,237 | $46.8M | 1.1% | −87,350 |
| State Street Corp | 1,617,475 | $36.5M | 0.0% | +87,844 |
| Geode Capital Management, LLC | 1,484,163 | $33.5M | 0.0% | +120,663 |
| Fmr LLC | 1,444,878 | $32.6M | 0.0% | −17,026 |
| Wellington Management Group Llp | 1,274,004 | $28.8M | 0.0% | +412,399 |
| Federated Hermes, Inc. | 1,253,420 | $28.3M | 0.0% | +1,078,984 |
| Jupiter Topco LLC | 1,103,404 | $24.9M | 0.0% | New |
| Frontier Capital Management Co LLC | 1,091,528 | $24.6M | 0.2% | +481,671 |
| Soleus Capital Management, L.P. | 1,003,000 | $22.6M | 0.8% | +843,000 |
| Champlain Investment Partners, LLC | 981,381 | $22.2M | 0.6% | −154,941 |
| Baillie Gifford & Co | 911,751 | $20.6M | 0.0% | −61,751 |
| Fiera Capital Corp | 774,569 | $17.5M | 0.1% | −193,026 |
| LMR Partners LLP | 721,608 | $16.3M | 0.1% | New |
| William Blair Investment Management, LLC | 709,484 | $16.0M | 0.0% | +285,175 |
| Artisan Partners Limited Partnership | 682,588 | $15.4M | 0.0% | −504,761 |
| Millennium Management LLC | 624,312 | $14.1M | 0.0% | −381,146 |
| Morgan Stanley | 605,407 | $13.7M | 0.0% | −372,000 |
| Northern Trust Corp | 597,549 | $13.5M | 0.0% | +45,531 |
| Blair William & Co/il | 531,724 | $12.0M | 0.0% | +207,789 |
| New York State Common Retirement Fund | 524,358 | $11.8M | 0.0% | +84,302 |
| Bank Of America Corp /de/ | 516,198 | $11.7M | 0.0% | −114,491 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARReza Zadno, Chief executive officer
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARLarry L. Wood, Board member
- 19SEC EDGARThomas M. Prescott, Board member
- 20SEC EDGARMary Garrett, Board member
- 21SEC EDGARAmy M. Dodrill, Board member
- 22SEC EDGARAntal Rohit Desai, Board member
- 23SEC EDGARFrederic H. Moll, Board member
- 24SEC EDGARMorgan Colby Wood, Board member
- 25SEC EDGARTaylor C. Harris, Board member
- 26SEC EDGARThomas M. Krummel, Board member
- 27SEC EDGARElisabeth Sandoval, Board member
- 28SEC EDGARAlaleh Nouri, General counsel
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37